Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 17, 2011

View Archived Issues

RVX-208 does not significantly raise ApoA-I levels in ASSERT trial

Overall success rate of clinical drug development is 9%

Taiwanese scientists use [18F]-FDG PET to predict survival of patients with OSCC

Antiestrogen therapy for breast cancer may reduce risk of mortality from lung cancer

Vernalis presents new inhibitors of serine/threonine-protein kinase Chk1

Astellas reviews highlights of third quarter fiscal year 2010

New cytotoxic chalcone derivatives claimed by Adamed

Pfenex and Boehringer Ingelheim form strategic alliance for novel technology

Eli Lilly achieves milestone in Mirror Portfolio venture

New modulators claimed of metabotropic glutamate mGlu4 receptor

Irish scientists patent new metal complexes for cancer therapy

GSK divulges new agents for treatment of HIV infections

INTERCEPT-prepared plasma receives FDA orphan drug status in TTP

Endo Pharma and Bioniche begin enrollment in second phase III trial of Urocidin

Aeolus receives U.S. government contract to develop AEOL-10150 for lung ARS

Spanish Ministry of Health grants full reimbursement for Sativex in MS-related spasticity

Rockwell Medical initiates PRIME trial examining use of SFP in hemodialysis

PharmaGap contracts NLI to develop liposomal GAP-107B8 formulation

Astellas and Aveo sign agreement for tivozanib outside of Asia

NICE recommends use of Vidaza for treatment of MDS and AML

Pro-Pharma receives final tranche from QTDP grant

Enrollment begins in phase II trial of carboplatin and paclitaxel plus Reolysin in pancreatic cancer

Phase III Chinese trial of Dromos in peripheral arterial diseases meets primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...